The discussion at Thursday’s FDA advisory committee meeting on a COVID-19 vaccine from Moderna and NIH highlighted the increasing difficulties of conducting trials as more vaccines become ...
In a blow to what has been one of the more successful drug launches of the year, Operation Warp Speed has commandeered some of Horizon’s manufacturing slots for thyroid eye disease ...
Following the early success of anti-TIGIT mAbs in clinical development this year, interest in next-generation checkpoints has been on the rise, and there’s reason to believe that checkpoints ...
Incubated by Atlas Venture and led by former Ipsen CBO Ivana Magovčević-Liebisch, Vigil launched last week with $50 million in series A financing to advance two TREM2 agonists ...
GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma ...
Cadent’s neuropsychiatry portfolio gives Novartis clinical programs in an area that the pharma has been eyeing for business development opportunities. Novartis AG (NYSE:NVS; SIX:NOVN) ...
Ultragenyx gains ex-Europe rights to Mereo’s setrusumabUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) licensed ex-European rights to setrusumab from Mereo BioPharma Group plc (LSE:MPH; ...
Recently launched European investment vehicle AurorA Science has placed its first marker on a company going after one of life sciences’ most infamous oncogene targets: MYC. AurorA Science ...
Samsung Biologics promoted EVP John Rim to president and CEO. Before joining the South Korean company in 2018, Rim worked for Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit for 14 years in ...
BioCentury ISSN 1097-7201
